TY - JOUR
T1 - Updating the psoriatic arthritis (PsA) core domain set
T2 - A report from the PsA workshop at OMERACT 2016
AU - Orbai, Ana Maria
AU - De Wit, Maarten
AU - Mease, Philip J.
AU - Duffin, Kristina Callis
AU - Elmamoun, Musaab
AU - Tillett, William
AU - Campbell, Willemina
AU - FitzGerald, Oliver
AU - Gladman, Dafna D.
AU - Goel, Niti
AU - Gossec, Laure
AU - Hoejgaard, Pil
AU - Leung, Ying Ying
AU - Lindsay, Chris
AU - Strand, Vibeke
AU - Van Der Heijde, Désirée M.
AU - Shea, Bev
AU - Christensen, Robin
AU - Coates, Laura
AU - Eder, Lihi
AU - McHugh, Neil
AU - Kalyoncu, Umut
AU - Steinkoenig, Ingrid
AU - Ogdie, Alexis
N1 - Publisher Copyright:
© Copyright 2017 The Journal of Rheumatology. All rights reserved.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Full Release Article. For details see Reprints and Permissions at jrheum.org ABSTRACT. Objective. To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS). Methods.At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants. Results. We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient's global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda. Conclusion. The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.
AB - Full Release Article. For details see Reprints and Permissions at jrheum.org ABSTRACT. Objective. To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS). Methods.At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. The updated PsA Core Domain Set was voted on and endorsed by OMERACT participants. Results. We conducted a systematic literature review of domains measured in PsA RCT and LOS, and identified 24 domains. We conducted 24 focus groups with 130 patients from 7 countries representing 5 continents to identify patient domains. We achieved consensus through 2 rounds of separate surveys with 50 patients and 75 physicians, and a nominal group technique meeting with 12 patients and 12 physicians. We conducted a workshop and breakout groups at OMERACT 2016 in which findings were presented and discussed. The updated PsA Core Domain Set endorsed with 90% agreement by OMERACT 2016 participants included musculoskeletal disease activity, skin disease activity, fatigue, pain, patient's global assessment, physical function, health-related quality of life, and systemic inflammation, which were recommended for all RCT and LOS. These were important, but not required in all RCT and LOS: economic cost, emotional well-being, participation, and structural damage. Independence, sleep, stiffness, and treatment burden were on the research agenda. Conclusion. The updated PsA Core Domain Set was endorsed at OMERACT 2016. Next steps for the PsA working group include evaluation of PsA outcome measures and development of a PsA Core Outcome Measurement Set.
KW - Core set
KW - Outcome measures
KW - Psoriatic arthritis
UR - http://www.scopus.com/inward/record.url?scp=85021213090&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021213090&partnerID=8YFLogxK
U2 - 10.3899/jrheum.160904
DO - 10.3899/jrheum.160904
M3 - Article
C2 - 28148697
AN - SCOPUS:85021213090
SN - 0315-162X
VL - 44
SP - 1522
EP - 1528
JO - Journal of Rheumatology
JF - Journal of Rheumatology
IS - 10
ER -